Protocol Ledger

NCT06685978 · Phase III · RECRUITING

Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands

Interventional Phase III clinical trial protocol NCT06685978 sponsored by Tasly Pharmaceutical Group Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-26 Enrollment: 430 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06685978
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)430 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06685978
Protocol FieldVerified Registry Value
NCT IdentifierNCT06685978
Consolidated Lead SponsorTasly Pharmaceutical Group Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment430 participants (ESTIMATED)
Registered Start Date2024-04-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06685978
Hospital Research SiteLocationSite Profile
Xuzhou central HospitalXuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI